新的癌症免疫疗法显示了希望,在24%的GI癌症患者中肿瘤减少。 New cancer immunotherapy shows promise, shrinking tumors in 24% of patients with GI cancers.

在治疗转移性胃肠癌方面,利用淋巴细胞(TILs)渗入肿瘤,加上苯丙氨基氨基甲酸酯,一种新的免疫疗法取得了令人乐观的成果。 A new immunotherapy using tumor infiltrating lymphocytes (TILs) combined with pembrolizumab has shown promising results in treating metastatic gastrointestinal cancers. 在临床试验中,近24%的患者发现瘤大小显著减少,而没有服用布罗利祖马布的患者则为7. 7%. In a clinical trial, nearly 24% of patients saw a significant reduction in tumor size, compared to 7.7% who received TILs without pembrolizumab. 由NIH研究人员牵头的治疗为治疗各种固态肿瘤带来了希望,尽管还需要开展更多的研究,以了解潜在的副作用和功效。 The therapy, led by NIH researchers, offers hope for treating various solid tumors, though more research is needed to understand potential side effects and efficacy.